@Article{096504018X15213115046567,
AUTHOR = {Gang Li, Tie Chong, Jie Yang, Hongliang Li, Haiwen Chen},
TITLE = {Kinesin Motor Protein KIFC1 Is a Target Protein of miR-338-3p and Is  Associated With Poor Prognosis and Progression of Renal Cell Carcinoma},
JOURNAL = {Oncology Research},
VOLUME = {27},
YEAR = {2019},
NUMBER = {1},
PAGES = {125--137},
URL = {http://www.techscience.com/or/v27n1/48668},
ISSN = {1555-3906},
ABSTRACT = {KIFC1 (kinesin family member C1) plays a critical role in clustering of extra centrosomes in various cancer 
cells and thus could be considered as a promising therapeutic target. However, whether KIFC1 is involved 
in the procession of renal cell carcinoma (RCC) still remains unclear. In this study, we found that KIFC1 was 
upregulated in RCC tissues and is responsible for RCC tumorigenesis (<i>p</i><0.001). The high expression of 
KIFC1 correlates with aggressive clinicopathologic parameters. Kaplan–Meier analysis suggested that KIFC1 
was associated with poor survival prognosis in RCC. Silencing KIFC1 dramatically resulted in inhibition of 
proliferation, delayed the cell cycle at G<sub>2</sub>/M phase, and suppressed cell invasion and migration in vitro. The 
antiproliferative effect of KIFC1 silencing was also observed in xenografted tumors in vivo. miR-338-3p could 
directly bind to the 3 -untranslated region (3 -UTR) of KIFC1, and ectopic miR-338-3p expression mimicked 
the inhibitory functions of KIFC1 silencing on RCC cells through inactivation of the PI3K/AKT signaling 
pathway. Therefore, these results revealed that KIFC1 may be a novel biomarker and an effective therapeutic 
target for the treatment of RCC.},
DOI = {10.3727/096504018X15213115046567}
}